Is miR therapeutic targeting still a miRage?

Elena Levantini

doi:10.52586/4979

Is miR therapeutic targeting still a miRage?

Front Biosci (Landmark Ed). 2021 Oct 30;26(10):680-692. doi: 10.52586/4979.

Author

Elena Levantini^{1

2

3

4}

Affiliations

¹ Harvard Medical School, Boston, MA 02115, USA.
² Beth Israel Deaconess Medical Center, Boston, MA 02215, USA.
³ Harvard Stem Cell Institute, Cambridge, MA 02138, USA.
⁴ Institute of Biomedical Technologies, National Research Council (CNR), Area della Ricerca di Pisa, 56124 Pisa, Italy.

PMID: 34719197
DOI: 10.52586/4979

Abstract

Since the discovery of the first microRNA (miR), almost three decades ago, the roles played by miRs under normal and diseased settings have been widely investigated. miRs are found to play crucial roles in cancer initiation and progression, as well as towards therapy response mechanisms. Therefore, they are relevant and attractive targets for therapeutic development. Many preclinical studies have demonstrated their promise as future anti-cancer tools. Recently, increasing number of early phase clinical trials have emerged. In this Commentary, we will summarize the major discoveries within the miR research field and highlight the status quo of current miR-therapeutics, which has prominent potential of impacting future cancer regimens given their massive dysregulation in oncogenic processes.

Keywords: Biomarkers; Cancer; NSCLC; RNA therapeutics; miR-21.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Humans
MicroRNAs* / genetics
Neoplasms* / drug therapy
Neoplasms* / genetics

Substances

MicroRNAs